Tech Company Financing Transactions

Tarsa Therapeutics Funding Round

Tarsa Therapeutics closed a $28 million Series B financing round on 3/19/2012. Investors included Foresite Capital, Novo Ventures and Quaker Partners.

Transaction Overview

Company Name
Tarsa Therapeutics
Announced On
3/19/2012
Transaction Type
Venture Equity
Amount
$28,000,000
Round
Series B
Investors

Foresite Capital (Lead Investor) (James Tananbaum)

Novo Ventures (Martin Edwards)

Quaker Partners (Matthew Rieke)

Proceeds Purpose
Following positive Phase III results and a successful pre-NDA meeting with the FDA, Tarsa is preparing to file a New Drug Application (NDA) with the US Food and Drug Administration (FDA) later this year for OSTORA, its oral calcitonin tablet for the treatment of postmenopausal osteoporosis

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
8 Penn Center 1628 John F. Kennedy Blvd. 1400
Philadelphia, PA 19103
USA
Phone
(267) 273-7940
Website
www.tarsatherapeutics.com
Email Address
[email protected]
Overview
Tarsa Therapeutics is developing an oral formulation of calcitonin, a peptide hormone for the treatment of osteoporosis that slows the rate of bone destruction.
Profile
Tarsa Therapeutics LinkedIn Company Profile
Social Media
Tarsa Therapeutics Company Twitter Account
Company News
Tarsa Therapeutics News
Facebook
Tarsa Therapeutics on Facebook
YouTube
Tarsa Therapeutics on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
David Brand
  David Brand LinkedIn Profile  David Brand Twitter Account  David Brand News  David Brand on Facebook
Chief Medical Officer
David Krause
  David Krause LinkedIn Profile  David Krause Twitter Account  David Krause News  David Krause on Facebook
Chief Scientific Officer
James Gilligan
  James Gilligan LinkedIn Profile  James Gilligan Twitter Account  James Gilligan News  James Gilligan on Facebook
VP - Regulatory Affairs
Nicholas LaBella
  Nicholas LaBella LinkedIn Profile  Nicholas LaBella Twitter Account  Nicholas LaBella News  Nicholas LaBella on Facebook

 

 

Browse more venture capital transactions:

Prev: 3/19/2012: Social Rewards venture capital transaction
Next: 3/20/2012: Slated venture capital transaction

 

Share this article

 

About Database of VC Transactions

We do our best to report on every notable VC transaction. All VC database entries on this site are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.